CSI Market
Sign In | Register

Astrazeneca Plc (AZN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AZN Annual Cash Flow →
This page allows investors to follow Astrazeneca Plc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income12,402.00
Depreciation & amortization5,733.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets-13.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Interest Paid Classified As Operating Activities201.00
Adjustments For Decrease Increase In Inventories-
Adjustments For Increase Decrease In Trade Other Payables And Provisions-
Adjustments For Losses Gains On Disposal Of Intangible Asset-
Contingent Consideration Fair Value Movement-
Other Adjustments For Noncash Items-
Adjustments For Finance Income Cost-
Income taxes0.00
Losses/ -gains on Investments net-7.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities21,437.00
Discontinued operations0.00
Net Cash flow from Operating Activities14,575.00
Investing Activities
Capital Expenditures2,810.00
Sale of Capital Items13.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Interest Received Classified As Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans452.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Other Cash Payments To Acquire InterestsIn Joint Ventures Classified As Investing Activities10.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-4,287.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-6,808.00
Financing Activities
Short-term debt Net364.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-8,366.00
Cash And Cash Equivalents If Different From Statement Of Financial Position-
Payment Of Share Purchase Liabilities-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid4,971.00
Net Cash Flow from Financing Activities-7,544.00
Effect of exchange rate on cash flow223.00
Discontinued operations0.00
Free Cash Flow17,398.00
Total Cash Flow446.00
4 historic quarters locked

Sign in to unlock the full Astrazeneca Plc cash flow history.

Sign In Create Free Account

About Astrazeneca Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-067039

Figures are derived from filed reports and may be restated. Historical data is subject to revision.